Introduction/Background Neoadjuvant chemotherapy (NACT) - Interval debulking surgery (IDS) can reduce the complexity of the surgery, and the incidence of perioperative complications and provide patients with the opportunity for satisfactory tumors. Also, it has the advantages of reduced intraoperative bleeding, lower perioperative complication rates, shorter hospital stays, less postoperative pain, and earlier postoperative discharge. NACT-IDS is recommended when no residual tumor (RO) is considered unachievable because of tumor location and patient‘s performance status or because of high volume stage IIC-IV dis

Methodology All patients received NACT, Cis-platinum 50 mg/m2/day 2–3; Paclitaxel 175 mg/m2/day 1; 5-fluorouracil (5FU) 800 mg/m2/day 1–2-3. Four cycles, every 21 days, are given and the surgery was performed one month after the last cycle. IDS was .performed, utilizing A Vcare uterine manipulator placed vaginally. A veress needle is placed in the umbilicus for peritoneal insufflation. A 2 cm incision over the lower rim of the umbilicus was performed. The patient was placed in the Trendelenburg position, and the DaVinci SP robotic surgical system side-docked parallel to the right side of the patient. Patients underwent surgery to remove all visible and palpable tumors. Surgical procedures are performed as appropriate: 1. low complexity, hysterectomy, bilateral-scalping-oophorectomy, omentectomy, pelvic lymphadenectomy, para-aortic lymphadenectomy, abdominal peritoneum strippings, and small bowel resections. 2. intermediate complexity, large bowel resection, diaphragm stripping/resections, splenectomy, and liver resections. 3. high complexity, recto-sigmoidectomy with anastomosis. Abdominal incisions are closed with O vicryl sutures.

Results The operating time was maintained at 190 minutes, and the console time was 130 minutes. The estimated blood loss was 100 ml. Patients had an uneventful recovery and were discharged home 2 days following surgery.

Conclusion Farghaly’s technique of robot-assisted NACT-IDS for advanced-stage ovarian cancer is feasible and has the advantage of decreasing morbidity, reducing the risk of dissemination, and short hospital stays.

Disclosures None.